Teriparatide is under clinical development by Corium and currently in Phase II for Osteoporosis. According to GlobalData, Phase II drugs for Osteoporosis have a 57% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Teriparatide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Teriparatide overview
Teriparatide (MicroCor hPTH (1-34)) is under development for the treatment of osteoporosis. The drug candidate is administered through the transdermal route. It is a shortened version of the naturally occurring parathyroid hormone that promotes bone growth. It is developed based on the MicroCor technology. This technology facilitates the easy delivery of parathyroid hormone.
Corium overview
Corium, Inc. (Corium), is commercial-stage biopharmaceutical company, which is a producer and developer of central nervous system pharmaceutical products. The company develops transdermal healthcare products with the help of Corplex technology platform using small molecules. Its products include Corplex Memantine and Corplex Donepezil for the treatment of Alzheimer’s disease. Corium also provides proprietary development programs, contract research and development services. It partners with pharmaceutical and consumer products companies. The company operates through its research and development facility in Grand Rapids, the US. Corium is headquartered in Menlo Park, California, the US.
For a complete picture of Teriparatide’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
